Cytotoxic and targeted systemic therapy in advanced and recurrent cervical cancer: experience from clinical trials
about
Molecular mechanisms of cisplatin resistance in cervical cancerNovel 1, 3-N, O-Spiroheterocyclic compounds inhibit heparanase activity and enhance nedaplatin-induced cytotoxicity in cervical cancer cells.HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER InhibitorsKlotho expression in cervical cancer: differential expression in adenocarcinoma and squamous cell carcinoma.
P2860
Cytotoxic and targeted systemic therapy in advanced and recurrent cervical cancer: experience from clinical trials
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Cytotoxic and targeted systemi ...... xperience from clinical trials
@ast
Cytotoxic and targeted systemi ...... xperience from clinical trials
@en
Cytotoxic and targeted systemi ...... xperience from clinical trials
@nl
type
label
Cytotoxic and targeted systemi ...... xperience from clinical trials
@ast
Cytotoxic and targeted systemi ...... xperience from clinical trials
@en
Cytotoxic and targeted systemi ...... xperience from clinical trials
@nl
prefLabel
Cytotoxic and targeted systemi ...... xperience from clinical trials
@ast
Cytotoxic and targeted systemi ...... xperience from clinical trials
@en
Cytotoxic and targeted systemi ...... xperience from clinical trials
@nl
P2093
P3181
P356
P1476
Cytotoxic and targeted systemi ...... xperience from clinical trials
@en
P2093
Hyun-Joo Seol
Jong-Min Lee
Roshani Ulak
P304
P3181
P356
10.1620/TJEM.232.269
P407
P50
P577
2014-04-01T00:00:00Z